Press Releases
Myrtelle’s Phase 1/2 clinical trial introduces first-of-its-kind proprietary recombinant adeno-associated virus (rAAV) vector designed to enable targeting of oligodendrocytes To date, 3 patients received gene therapy with the rAAV vector at a dose of 3.7 x 1013 vg delivered via intracerebroventricular administration Available follow-up data in treated patients demonstrate favorable safety and tolerability with encouraging initial…
Read More
Excerpt from the Press Release: Collaboration Enables Further Expansion of Mass Cytometry in the Middle East SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for…
Read More
SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced…
Read More
Excerpt from the Press Release: FREDERICK, Md. and BOSTON, Feb. 15, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for its OsteoAdapt SP Spinal Fusion implant indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis,…
Read More
– Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomography (OCT) through eight-month follow-up – 41% of eyes remained rescue free up to nine months after a single dose of EYP-1901 – Positive safety data continued with no dose limiting toxicities, no ocular serious adverse events (SAEs) and no drug-related…
Read More
Findings Highlight Potential of Oral Substrate Reduction Therapy to Lower Disease-Causing Glycogen Build-up as a Treatment for Pompe Disease Data Support Advancement of MZE001 into Phase 1 Clinical Trial Expected to Start in First Half of 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new…
Read More
— Data Supports the Continued Use of Veklury for Treatment of COVID-19 for Current SARS-CoV-2 Variants – Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today released data demonstrating the in vitro activity of Veklury® (remdesivir) against ten SARS-CoV-2 variants, including Omicron. Results of Gilead studies are consistent with other in vitro studies independently conducted…
Read More
– Preclinical study data indicate that intranasal administration of enkephalin (Envelta) is well-tolerated and safe – Excerpt from the Press Release: BERWYN, Pa.–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, reported promising results from preclinical dose…
Read More
Longer-term data in 20 patients show sustained normalization to healthy levels of CSF heparan sulfate and improvements in markers of lysosomal function consistent with durable CNS activity, now with up to one year of intravenous dosing with DNL310 Safety profile with up to 56 weeks of dosing remains consistent with standard-of-care enzyme replacement therapy Data…
Read More
Company to unveil new preclinical data for SG-5-00455 at 17th Congress of European Crohn’s and Colitis Organization (ECCO) plenary session on February 18, 2022 Virtual key opinion leader (KOL) event hosted by Company on role of mucosal healing andPAI-1/2 in IBD to occur on Wednesday, February 23 at 12 p.m. EST Excerpt from the Press…
Read More